CAS: 22457-89-2; S-(2-(N-((4-Amino-2-Methylpyrimidin-5-yl)Methyl)Formamido)-5-(Phosphonooxy)Pent-2-En-3-yl) Benzothioate

维生素b1置于sodium Hydroxide体系中,用 水 用作溶剂,化学反应 4.0H,反应生成苯磷硫胺
参考文献:一种苯磷硫胺的生产方法
标题:一种苯磷硫胺的生产方法
摘要:一种苯磷硫胺的生产方法,以多聚磷酸为磷酸酯化试剂,与维生素b1反应,反应完后高温下水解,水解完后,用三辛胺与有机溶剂的混合溶液萃取体系的磷酸后,直接加有机溶剂析出维生素b1的磷酸单酯粗品.得到的粗品不经提纯,直接用水打浆,用液碱调ph值后,与苯甲酰氯反应,过滤固体.滤液调ph值至3.5~4.0析出固体,分离并烘干得到白色固体,即为苯磷硫胺.用该工艺生产得到的苯磷硫胺产率高,产品纯度高,操作简单,对环境友好,适合工业化生产.

专利信息

专利号:US-2022378721-A1
优先权日:2019-10-24
标 题 :Protein kinase inhibitors and use thereof for treatment of neurodegenerative diseases
发明人：SRIDHAR JAYALAKSHMI; BRATTON MELYSSA; GOYAL NAVNEET; JHA VISHWAJEET; SCHROEDER RICHARD
权利人:XAVIER UNIV OF LOUISIANA
摘要:The present disclosure relates to compounds that act as protein kinase inhibitors, especially CK1δ and/or CK1ε inhibitors, which can be used to treat a serine threonine kinase-dependent disease and condition, such as neurodegenerative diseases like Alzheimer's Disease, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for neurodegenerative diseases, including Alzheimer's disease.

专利号:US-2022160788-A1
优先权日:2019-03-22
标题 :Bifunctional vectors allowing bcl11a silencing and expression of an anti-sickling hbb and uses thereof for gene therapy of b-hemoglobinopathies
发明人：MICCIO ANNARITA; AMENDOLA MARIO; BRUSSON MÉGANE; CAVAZZANA MARINA; MAVILIO FULVIO
权利人:INST NAT SANTE RECH MED; UNIV DEVRY VAL DESSONNE; ASSIST PUBLIQUE HOPITAUX PARIS APHP; UNIV PARIS; FOND IMAGINE
摘要:The #β-hemoglobinopathies #β-thalassemia (BT) and sickle cell disease (SCD) are the most frequent genetic disorders worldwide. These diseases are caused by mutations causing reduced or abnormal synthesis of the β-globin chain of the adult hemoglobin (Hb) tetramer. Here, the inventors intend to improve HSC-based gene therapy for β-thalassemia and SCD by developing an innovative, highly infectious LV vector expressing a potent anti-sickling β-globin transgene and a second biological function either increasing fetal γ-globin expression (for β-thalassemia and SCD). More particularly, the inventors have designed a novel lentivirus (LV), which carry two different functions: βAS3 gene addition and gene silencing. This last strategy allows the re-expression of the fetal γ-globin genes (HBG1 and HBG2) and production of the endogenous fetal hemoglobin (HbF). Elevated levels of HbF and HbAS3 (Hb tetramer containing βAS3-globin) will benefit the β-hemoglobinopathy phenotype by increasing the total amount of β-like globin that will: (i) reduce the alpha precipitates and improve the alpha/non alpha ratio in β-thalassemia, and (ii) reduce the sickling in SCD. This combined strategy will improve the β-hemoglobinopathy phenotype at a lower vector copy number (VCN) per cell compared to a LV expressing the βAS3 alone.

专利号:US-RE49935-E
优先权日:2012-10-17
标 题:Crystalline polymorphs of benfotiamine, process for preparation and its use thereof
发明人：ZHONG CHUNJIU; HE YINHUA; MEI XUEFENG; ZHANG HUAN
权利人:SHANGHAI RAISING PHARMACEUTICAL CO LTD
摘要:The present invention is directed to crystalline polymorphs of benfotiamine, its methods of preparation and its use thereof. Five crystalline polymorphs of benfotiamine are designated as crystalline forms A, B, C, D and E, and may be distinguished by their respective patterns of X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), infrared spectroscopy (IR), raman spectroscopy, moreover by their diverse preparing process. The crystalline polymorphs of the present invention are useful as they act in treating Vitamin B1 deficiency, metabolic disorders, mental illness and disorders, diabetes complications, neurodegerative diseases. Further the present invention is a process for preparing and transforming diverse crystalline form of benfotiamine through different synthesis routes and varied solvents and combinations. The crystalline polymorphs of the present invention are basically pure. The present invention not only provides new crystalline forms of benfotiamine, but also provides its new solvates, especially hydrates.

专利号:US-8241607-B2
优先权日:2005-08-24
标题 :Use of fructose-based compounds for the diagnosis of cancer
发明人：HEANEY ANTHONY P; HUI HONGXIANG; WAXMAN ALAN
权利人:HEANEY ANTHONY P; HUI HONGXIANG; WAXMAN ALAN; CEDARS SINAI MEDICAL CENTER
摘要:This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of these features and provides for fructose or fructose-based compositions for the diagnosis of cancer using imaging techniques such as positron emission tomography.

专利号:US-2005182036-A1
优先权日:2002-08-02
标题:Medicinal composition containing an HMG-CoA reductase inhibitor
发明人：KONDO TATSUHITO; TAKAGI IKUO; NAKAYAMA MASATO; TORIZUMI YASUHIRO
权利人:SANKYO CO
摘要:A pharmaceutical composition for promoting the synthesis of vascular endothelial nitrogen oxide and/or maintaining or elevating the concentration of vascular endothelial nitrogen oxide in the blood, or a pharmaceutical composition for improving blood lipids. The pharmaceutical composition contains an HMG-CoA reductase inhibitor; and gamma-oryzanol, and/or thiamines. For treatment, the components of the composition can be administered together, as a composition, or separately.

专利号:US-9907753-B2
优先权日:2010-03-19
标 题 :Lipid vesicle compositions and methods of use
发明人：IRVINE DARRELL J; MOON JAEHYUN
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.